

ELRIG Drug Discovery 2019
5th and 6th November 2019

Poster Title

Deeper understanding of drug and disease - Emerging Biomarker Technologies.

Gayle Marshall, Kerry Shea, Andrzej Rutkowski, Juliana Maynard, Philippa Hart, Martin Bachman, Sally Price and Peter Simpson - Medicines Discovery Catapult (MDC).

MDC are developing more translational models that better reflect the patient population, to address the poor correlation between clinical and animal data. Biomarker analysis is key in demonstrating a models reflection of patient disease.

Neuroinflammation is a complex integration of the responses of all cells present within the CNS, including the neurons, macroglia, microglia and the infiltrating leukocytes. Neuron-microglia co-cultures treated with pro-inflammatory agents are a useful tool to study neuroinflammation in vitro.

How do we know these in vitro tools represent patient disease?

Here we describe a range of emerging biomarker technologies used to characterise drug and disease such as pre-clinical animal and mass spec imaging, along with digital spatial profiling platforms to demonstrate back translation from patient to the bench.